Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 11/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | BCL6 | P41182 | 5/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.45 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | MELK | Q14680 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23268167 | 0.95 | PTK2 (0.49) | PTK2CRBNBTKBCL6NCOR2 | |
| SCHEMBL31595434 | 0.95 | CRBN (0.47) | PTK2CRBNBTKAR | |
| SCHEMBL29874152 | 0.91 | BCL6 (0.57) | PTK2CRBNBTKBCL6NCOR2 | |
| SCHEMBL23249960 | 0.91 | BCL6 (0.57) | PTK2CRBNBTKBCL6NCOR2 | |
| SCHEMBL23249916 | 0.91 | BCL6 (0.57) | PTK2CRBNBTKBCL6NCOR2 | |
| SCHEMBL29874253 | 0.91 | BCL6 (0.57) | PTK2CRBNBTKBCL6NCOR2 | |
| SCHEMBL31595205 | 0.90 | PTK2 (0.50) | PTK2CRBNBTKBCL6NCOR2 | |
| SCHEMBL23267394 | 0.90 | PTK2 (0.50) | PTK2CRBNBTKBCL6NCOR2 | |
| SCHEMBL31595518 | 0.90 | PTK2 (0.53) | PTK2CRBNBTKAR | |
| SCHEMBL23266220 | 0.90 | PTK2 (0.53) | PTK2CRBNBTKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | PTK2 3371/4885CRBN 5/4885BTK 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.